
Vincent Meininger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5353793/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Causes of death in a postâ€mortem series of ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 59-62.	2.1	140
2	Progression in ALS is not linear but is curvilinear. Journal of Neurology, 2010, 257, 1713-1717.	3.6	124
3	Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. International Journal of Cancer, 1990, 46, 262-266.	5.1	107
4	Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 107-117.	1.2	104
5	Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 217-223.	2.1	98
6	BILATERAL TACTILE APHASIA: A TACTO-VERBAL DYSFUNCTION. Brain, 1978, 101, 381-401.	7.6	95
7	Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2005, 2, 166-176.	1.4	88
8	Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 378-383.	2.1	83
9	Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurology, The, 2016, 15, 1217-1227.	10.2	65
10	How can we improve clinical trials in amyotrophic lateral sclerosis?. Nature Reviews Neurology, 2011, 7, 650-654.	10.1	49
11	Radiation Therapy for Hypersalivation: A Prospective Study in 50 Amyotrophic Lateral Sclerosis Patients. International Journal of Radiation Oncology Biology Physics, 2014, 88, 589-595.	0.8	44
12	The loss of motorneurons corresponding to specific muscles in the wobbler mutant mouse. Neuroscience Letters, 1983, 37, 99-104.	2.1	41
13	Management of Amyotrophic Lateral Sclerosis. Drugs, 2008, 68, 1037-1048.	10.9	37
14	Postnatal modifications of the dendritic tree of cells in the inferior coliicuius of the cat. A quantitative Golgi analysis. Journal of Comparative Neurology, 1981, 200, 339-355.	1.6	35
15	Brain and Plasma Riluzole Pharmacokinetics: Effect of Minocycline Combination. Journal of Pharmacy and Pharmaceutical Sciences, 2009, 12, 209.	2.1	35
16	Improving survival in a large French ALS center cohort. Journal of Neurology, 2012, 259, 1788-1792.	3.6	33
17	Xaliproden in amyotrophic lateral sclerosis: early clinical trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 99-106.	1.2	24
18	Brain perfusion imaging in amyotrophic lateral sclerosis: Extent of cortical changes according to the severity and topography of motor impairment. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 9-15.	2.1	24

VINCENT MEININGER

#	Article	IF	CITATIONS
19	Coordinated care affects hospitalization and prognosis in amyotrophic lateral sclerosis: a cohort study. BMC Health Services Research, 2015, 15, 134.	2.2	22
20	Ciliogenesis and centriole formation in the mouse embryonic nervous system. An ultrastructural analysis. Biology of the Cell, 1988, 62, 165-169.	2.0	21
21	Organisation des motoneurones des muscles pectoraux chez le rat. Cells Tissues Organs, 1981, 109, 209-217.	2.3	20
22	Characteristics of Microtubules at the Different Stages of Neuronal Differentiation and Maturation. International Review of Cytology, 1989, 114, 21-79.	6.2	20
23	New therapy options for amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy, 2013, 14, 1907-1917.	1.8	19
24	Histogenesis of the inferior colliculus in rat. Anatomy and Embryology, 1982, 165, 19-37.	1.5	16
25	Biochemical basis of microtubule cold stability in the peripheral and central nervous systems. Brain Research, 1988, 450, 231-236.	2.2	16
26	Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans?. Neurodegenerative Diseases, 2005, 2, 208-214.	1.4	15
27	In situ appearance of the cold-stable microtubules in the growing axons of the tectal plate of mouse investigated immunocytochemically after polyethyleneglycol (PEG) embedding. Developmental Brain Research, 1987, 36, 171-180.	1.7	11
28	ALS, what new 144 years after Charcot?. Archives Italiennes De Biologie, 2011, 149, 29-37.	0.4	11
29	Heterogeneity of cold-stable and cold-labile tubulin in axon- and soma-enriched portions of the adult mouse brain. Neuroscience Letters, 1987, 77, 166-170.	2.1	9
30	Treatment of emotional lability in ALS. Lancet Neurology, The, 2005, 4, 70.	10.2	9
31	Lithium therapy in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 122-122.	2.1	9
32	The cytoarchitecture of the inferior colliculus in the cat. Journal of the Neurological Sciences, 1977, 34, 25-36.	0.6	7
33	Modifications of tubulin heterogeneity during axonal growth in the embryonic nervous system. Developmental Brain Research, 1988, 38, 296-299.	1.7	5
34	Spatial organization of microtubules in various types of cells in the embryonic tectal plate of mouse using immunofluorescence after PEG embedding. Biology of the Cell, 1988, 64, 301-308.	2.0	4
35	Clinical trials: the past, a lesson for the future. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 15-18.	1.2	3
36	Modifications of tubulin heterogeneity during embryonic and postnatal stages in a specific region of mouse brain. Brain Research, 1991, 548, 133-139.	2.2	2

#	Article	IF	CITATIONS
37	Survival endpoint: Summary. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, S41-S44.	1.2	2
38	European ALS Consortium. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 133-134.	1.2	2
39	Use of a modular ontology and a semantic annotation tool to describe the care pathway of patients with amyotrophic lateral sclerosis in a coordination network. PLoS ONE, 2021, 16, e0244604.	2.5	1
40	Bases anatomiques de la mémoire. Anatomia Clinica FranzoÌ^sische Ausgabe, 1980, 2, 275-282.	0.1	0